rasagiline (azilect) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Rasagiline (N-propargyl-1-(R)-aminoindan) is a selective, irreversible monoamine oxidase B (MAO B) inhibitor, which has been developed as an anti-Parkinson drug and was sold as a mesylate salt under brand name AZILECT. AZILECT is indicated for the treatment of the signs and symptoms of idiopathic Parkinson’s disease (PD) as initial monotherapy and as adjunct therapy to levodopa. The effectiveness of AZILECT was demonstrated in patients with early Parkinson’s disease who were receiving AZILECT as monotherapy and who were not receiving any concomitant dopaminergic therapy. The effectiveness of AZILECT as adjunct therapy was demonstrated in patients with Parkinson’s disease who were treated with levodopa. PD is a progressive neurodegenerative, dopamine deficiency disorder. The main therapeutic strategies for PD treatment relies on dopamine precursors (levodopa), inhibition of dopamine metabolism (monoamine oxidase [MAO] B and catechol-O-methyl transferase inhibitors), and dopamine receptor agonists. In contrast to selegiline, rasagiline is not metabolized to potentially toxic amphetamine metabolites. The precise mechanisms of action of rasagiline is unknown. One mechanism is believed to be related to its MAO-B inhibitory activity, which causes an increase in extracellular levels of dopamine in the striatum.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

Australia

$1.9279

United States

$2.0643 - $29.3139
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

(1r)-n-propargylindan-1-amine | 2,3-dihydro-n-2-propynyl-1h-inden-1-amine-(1r)-hydrochloride | agn 1135 | agn-1135 | azilect | n-2-propynyl-1-indanamine | n-propargyl-1-aminoindan mesylate | ras | rasagiline | rasagiline hydrochloride | rasagiline mesilate | rasagiline mesylate | rasagiline tartrate | (r)-indan-1-yl-prop-2-ynyl-amine | (r)-n-2-propynyl-1-indanamine | (r)-(+)-rasagiline | tv-1030 | tvp 101 | tvp-101 | tvp-1012 | tvp1022 | tvp 1022 | tvp-1022

Organizations (78)

Research & Development (65)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (14)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (16)

Approved Indications (1)


 

Parkinson Disease

Experimental Indications - Clinical Trial Phases 1-4 (16)


 

Alzheimer Disease (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 2)

Apathy (Phase 4)

Brain Injuries (Phase 1/Phase 2)

Dementia (Phase 2)

Depression (Phase 4)

Healthy Volunteers (Phase 1)

Multiple System Atrophy (Phase 2)

Parkinson Disease ()

REM Sleep Behavior Disorder (Phase 2/Phase 3)

Restless Legs Syndrome (Phase 2/Phase 3)

Retinal Detachment (Phase 4)

Schizophrenia (Phase 4)

Sleep Disorders, Intrinsic (Phase 4)

Supranuclear Palsy, Progressive (Phase 3)

Synucleinopathies (Phase 2/Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 56
  • # of Trial Organizations: 65

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue